Join to view full profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. Alhalabi is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2017 - 2020
Corewell Health East Beaumont (Royal Oak)Residency, Internal Medicine, 2014 - 2017
Damascus University Faculty of MedicineClass of 2013, MD
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2027
GA State Medical License 2023 - 2027
LA State Medical License 2023 - 2027
MS State Medical License 2023 - 2027
OK State Medical License 2023 - 2027
TN State Medical License 2023 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma Start of enrollment: 2023 Jun 13
- A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma Start of enrollment: 2019 Dec 18
Publications & Presentations
PubMed
- Divergent biology and outcomes of somatic transformations in germ cell tumors.Zachariah Thomas, Andrew C Johns, Michael Glover, Emanuele Crupi, Yago L Nieto
The Oncologist. 2026-07-08 - 8 citationsOutcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study.Tanya Jindal, Cindy Y Jiang, Omar Alhalabi, Charles B Nguyen, Eugene Oh
European Urology. 2026-07-01 - Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications.Can Aydogdu, Laura Bukavina, Liang Cheng, Hikmat A Al-Ahmadie, Omar Alhalabi
European Urology. 2026-06-26
Press Mentions
Has the Future of Bladder Cancer Care Arrived? Molecular Testing May Change Adjuvant StrategiesNovember 17th, 2025
MD Anderson Research Highlights for February 26, 2025February 26th, 2025- MD Anderson Unveils Groundbreaking Research Breakthroughs – February 26, 2025February 26th, 2025
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
